{"id":"NCT01290341","sponsor":"Merz North America, Inc.","briefTitle":"Evaluation of the Efficacy and Safety of NAFT-600 in Subjects With Tinea Pedis","officialTitle":"A Phase 3 Double-Blind, Randomized, Placebo-Controlled,Multicenter, Parallel Group Evaluation of the Efficacy and Safety of NAFT-600 in Subjects With Tinea Pedis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-02","primaryCompletion":"2011-11","completion":"2011-12","firstPosted":"2011-02-07","resultsPosted":"2013-09-26","lastUpdate":"2013-09-26"},"enrollment":860,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Tinea Pedis"],"interventions":[{"type":"DRUG","name":"NAFT-600 (naftin 2 % gel)","otherNames":["NaftinÂ®"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"NAFT-600 ( naftin 2 % gel)","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"This is a 6-week, double-blind, randomized, placebo-controlled, multicenter, parallel group Phase 3 study of NAFT-600 applied once a day for 2 weeks compared to vehicle (placebo) in the treatment of tinea pedis.","primaryOutcome":{"measure":"Complete Cure of Interdigital Tinea Pedis","timeFrame":"Visit 4/ Week 6","effectByArm":[{"arm":"NAFT-600","deltaMin":26,"sd":null},{"arm":"Placebo","deltaMin":3.3,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.025"}]},"eligibility":{"minAge":"12 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":11},"locations":{"siteCount":23,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":572},"commonTop":["Headache"]}}